Sign in
Knowstox

Fundamentals snapshot

Damora Therapeutics, Inc.

DMRA · NCM · Healthcare · Biotechnology

Current price

$23.25

52-week range

$15.76 - $38.33

Market cap

$1.44B

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-180.70x Concerning

Net cash $527.38M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Damora Therapeutics, Inc.

Damora Therapeutics, Inc. develops new medicines for blood disorders. Their main income is from selling these experimental treatments, which matters because it shows if their research is paying off and if they can bring life-changing drugs to patients.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Revenue —
Net income $-31.99M
Diluted EPS -0.40
Operating cash flow $-17.23M
Free cash flow —
Revenue —
Net income $-31.17M
Diluted EPS -0.39
Operating cash flow $-21.87M
Free cash flow —
Revenue —
Net income $-27.78M
Diluted EPS -0.62
Operating cash flow $-20.60M
Free cash flow —
Revenue —
Net income $-200.74M
Diluted EPS 10.86
Operating cash flow $566.00K
Free cash flow —
Revenue —
Net income $-3.13M
Diluted EPS -2.36
Operating cash flow $-2.62M
Free cash flow —
Revenue —
Net income $-3.44M
Diluted EPS -2.60
Operating cash flow $-2.24M
Free cash flow —
Revenue —
Net income $-2.53M
Diluted EPS -1.92
Operating cash flow $-2.44M
Free cash flow —
Revenue —
Net income $-6.74M
Diluted EPS -14.74
Operating cash flow $-4.94M
Free cash flow —

Is it cheap or expensive?

Fair value — vs current price $23.25

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $527.4M - more cash than debt. Interest coverage -180.7x.

Net debt $-527.38M
Interest coverage -180.70x

Damora Therapeutics, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.

Healthy
Worse cushion Baseline Better cushion
DMRA BASELINE Damora Therapeutics, Inc.

Total debt $1.10M Interest coverage -180.70x This is the baseline the peer rows are being compared against.

-180.70x

What you should know

The case for and against DMRA

0 Rewards 1 Risk

Rewards

Risks

  • Return on equity was -115.8% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
13.60x
Forward P/E
-10.64x
P/B
3.94x
P/S
—
EV/EBITDA
-8.01x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-115.8%
ROA
-29.9%

Health

Liquidity and balance-sheet strength

Debt / equity
0.00x
Current ratio
14.80x
Quick ratio
14.75x
Total debt
$1.10M
Total cash
$528.48M

Growth

How the business has been compounding

Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
1.71
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-59.13M
Free CF TTM
$-6.73M
FCF margin
—

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—